Meet the START cohorts
We’re proud to showcase the dynamic companies within the Founders at the University of Cambridge START accelerator programmes. Powering growth through science, each founding team is transforming IP-rich, deep tech ideas into companies that address global challenges, from climate change and mental health to treating diseases and improving food security.
Our Investor Day Lookbooks for START 1.0 and START 2.0 provide insights into the innovation and ingenuity these companies have created whilst reaching this new milestone of commercialising their life-long research. Take a look at…
Cambridge Adaptive Testing
Developing rapid, simple and precise mental health measurement using innovative technologies. Its age-specific platforms enable efficient mental health assessments to identify those in need of support.
Learn more
Electra Bio
Electra Bio is building bioelectronic lab-grown organs, making drug discovery smarter and faster.
Learn more
Gastrobody Therapeutics
Gastrobody Therapeutics is developing ultra-stable antibody mimetics capable of withstanding the harsh acidic and protease-rich conditions of the GI tract.
Learn more
Pinepeak
Pinepeak develops physics-driven technology to predict wildfire risk and behaviour across any terrain, anywhere in the world.
Learn more
Prodromic
Using AI to make brain health more intelligent, Prodromic is accelerating the development of new treatments to ensure each person gets the right intervention at the right time.
Learn more
Sqwish
Sqwish is the smart performance layer sitting between AI apps and model providers — dynamically optimising speed, performance, cost and reliability at scale, so developers get the best results without the overhead.
Learn more
Trismik
Trismik is dedicated to revolutionising the field of Large Language Model (LLM) testing, providing an adversarial platform that enhances model accuracy, safety, and alignment with societal values.
Learn more
Aetosense
AetoSense is on a mission to revolutionise control strategies around air quality with innovative ultrafine particle monitoring solutions. Their focus is on the critical impact of airborne particles on health and energy efficiency.
Pitch
BioTryp Therapeutics
By inhibiting biofilms, BioTryp’s technology has the potential to revolutionise how we treat infection, providing a much-needed alternative to traditional antibiotic treatment.
Pitch
Bravely Cultured
Using proprietary marine microbes, BravelyCultured is replacing animal, tropical oil, and petroleum-based products, starting with eco-friendly biosurfactants to replace their petroleum-derived counterparts.
Pitch
Cambridge Vision Technology
Cambridge Vision Technology has a secure and scalable system for the early detection of disease through a simple eye test, available at opticians.
Pitch
Molyon
Molyon is producing the next-gen energy storage solution: the lithium-sulfur battery. Offering long-life batteries with twice the energy density of current lithium-ion batteries, at a fraction of the price due to more abundant materials.
Pitch
Nanomation
Nanomation provides computer-vision software to the semiconductor industry, enabling clients to manufacture with advanced nanomaterials that are otherwise not usable within industry settings.
Pitch
Orbit
Orbit is revolutionising mental health by making it as clear and actionable as physical health, using groundbreaking non-invasive neurotechnology.
Pitch
Protonera
Protonera aims to realise the scalability of a novel plastic upcycling technology to transform waste plastics into green hydrogen and other value-added commodities.
Pitch
VOLTQUANT
Solving the biggest problem towards net-zero, fixing the UK electricity grid. VOLTQUANT offers the world’s first search engine for grid connections, empowering developers to connect seamlessly using a machine-learning-enabled platform.
Pitch
William Oak Diagnostics
William Oak Diagnostics is developing a point-of-care test for micronutrient deficiencies for maternal, infant and child health, bringing a better standard of health around the world.
Pitch
Xterna
Xterna’s technology identifies different cell types in the human body through engineered cell-specific binders. These binders could be used for diagnostics or coupled with therapeutics to aid drug delivery to specific cells.
BE THE FIRST TO HEAR ABOUT LATEST NEWS AND EVENTS
By submitting the form below you consent to Founders at the University of Cambridge contacting you by email in relation to news and updates.